XtalPi-Enabled PEP08 PRMT5 Inhibitor Begins Phase I Cancer Trial Enrollment

Key Takeaways

• PEP08, a next-generation PRMT5 inhibitor discovered using XtalPi’s AI platform, has successfully begun Phase I clinical trial enrollment for solid tumors
• The partnership between XtalPi and PharmaEngine has initiated a second synthetic lethality program following PEP08’s drug discovery success
• This milestone represents a significant advancement in AI-powered drug discovery translating to human clinical testing

---

SHENZHEN, China - XtalPi (2228.HK), a leading AI and robotics-powered drug discovery platform, announced that PEP08, a PRMT5 inhibitor developed through its strategic partnership with PharmaEngine (4162.TWO), has achieved a critical milestone by beginning patient enrollment in Phase I clinical trials for solid tumors.

AI-Powered Drug Discovery Success

PEP08 represents a next-generation approach to targeting PRMT5 (protein arginine methyltransferase 5), an enzyme increasingly recognized as a promising cancer target. The drug was discovered using XtalPi’s proprietary AI and robotics platform, demonstrating the potential of artificial intelligence to accelerate pharmaceutical development timelines.

PRMT5 inhibitors work through synthetic lethality mechanisms, selectively targeting cancer cells with specific genetic vulnerabilities while sparing healthy tissue. This approach offers potential advantages over traditional chemotherapy by reducing side effects and improving treatment precision.

Expanding Partnership Pipeline

Building on PEP08’s successful progression from discovery to clinical testing, XtalPi and PharmaEngine have launched a second collaborative project targeting synthetic lethality pathways. This expansion reflects growing confidence in the AI-driven drug discovery approach and suggests a robust pipeline of potential cancer treatments.

The partnership leverages XtalPi’s computational drug design capabilities with PharmaEngine’s clinical development expertise, creating a streamlined path from molecular discovery to patient treatment.

Market Implications

The successful transition of PEP08 into human trials validates AI-powered drug discovery platforms and could accelerate investor interest in similar technologies. PRMT5 inhibitors represent a competitive oncology space, with several pharmaceutical companies pursuing similar targets.

For patients with solid tumors, PEP08 offers potential access to a novel treatment mechanism that could complement or improve upon existing therapies, particularly for cancers with limited treatment options.

---

Frequently Asked Questions

What does this mean for cancer patients?

PEP08 offers a new treatment approach using synthetic lethality to selectively target cancer cells while potentially reducing side effects compared to traditional chemotherapy. However, it’s still in early Phase I trials to establish safety.

When will PEP08 be available to patients?

PEP08 is currently in Phase I trials, which typically take 1-2 years. If successful, Phase II and III trials would follow, meaning widespread availability is likely several years away, though patients may access it through clinical trials.

How does PEP08 compare to existing cancer treatments?

PEP08 targets PRMT5 through synthetic lethality, a newer approach that aims to be more selective than traditional chemotherapy. This could mean fewer side effects, but clinical trials are needed to prove its effectiveness compared to current treatments.